학술논문
ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer's disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial.
Document Type
Article
Author
Source
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2022 Supplement 10, Vol. 18 Issue 10, p1-2, 2p
Subject
Language
ISSN
15525260